gvtcx

Genome Plasmid

University Of Edinburgh Published 31 Mar 2026 Public Contracts Scotland

key details

ValueUSN 75,135
Statuscomplete
Category (CPV) 33140000
Procedureopen
OCIDocds-r6ebe6-0000801998

Award

SupplierValueDateStatus
Indiana University · · ·

description

We are planning a clinical trial to treat a rare genetic disease that causes progressive dementia in children. Our therapy is based on the following: Autologous haematopoietic stem progenitor cells (HSPCs) are modified ex vivo with a lentiviral vector (LV) to express supraphysiologic levels of a secreted enzyme in myeloid progeny, in essence using gene-modified monocytes/macrophages as a durable and effective vehicle for central nervous system (CNS) enzyme delivery.

In order to progress this therapy, we require the following; a plasmid to our specification, produced to FDA, IND ready standard for use in the manufacture of a lentiviral vector for clinical trial. This Plasmid will be delivered directly from the supplier to the University of Edinburgh’s partner in the project, University of California Los Angeles.

documents

Documents are linked, not mirrored. They are served by the publishing authority and may require registration.

more from University Of Edinburgh

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Public Contracts Scotland. Contact details for named individuals are not reproduced on this site.